Where does Agios Pharmaceuticals, Inc. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Agios Pharmaceuticals, Inc. ranks #3,953 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Agios Pharmaceuticals, Inc. hold?

Agios Pharmaceuticals, Inc. holds 91 US utility patents granted between 2015 and 2025, spanning 16 technology areas.

What is Agios Pharmaceuticals, Inc.'s Innovation Score?

Agios Pharmaceuticals, Inc. has an Innovation Score of 45.3 out of 100 (top 23% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

Is Agios Pharmaceuticals, Inc.'s patent grant rate increasing or decreasing?

Agios Pharmaceuticals, Inc.'s recent grant velocity is -41% compared to the prior five-year period (grant years, not application filing dates). Grant activity has slowed relative to earlier years.

What does claim depth mean for Agios Pharmaceuticals, Inc.'s patents?

Agios Pharmaceuticals, Inc.'s patents average 20.6 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Agios Pharmaceuticals, Inc. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView US Corporation

Agios Pharmaceuticals, Inc.

Q: What technology areas does Agios Pharmaceuticals, Inc. focus on?

Agios Pharmaceuticals, Inc.'s top technology area is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations) with 80 patents. Grants appear in 16 CPC subclasses total.

USPTO PatentsView assignee record - 91 granted patents across 16 technology areas, recorded in grant years 2015–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Agios ranks #3,953 of 49,997 tracked US assignees by granted-patent volume, with 91 patents across 16 technology areas.

#3,953
of 49,997 US assignees by volume: Top 23%
by Innovation Score (45.3/100): 20.6
avg claims per patent: -41%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R3953 · US Corporation #3,953 · 91 grants

GRANTS-SMALL · TOP-DECILE · PHOTO-FINISH · CPC-FOCUS · INNOV-PAR · CLAIMS-DENSE · TYPE-USCORP · VEL-DROP · BOOK-FULL

GRANTS-SMALL 91 grants
TOP-DECILE #3,953/49,997
PHOTO-FINISH Abiomed Europe
CPC-FOCUS A61P · 16 areas
INNOV-PAR 45.3/100
CLAIMS-DENSE 20.6 claims/avg
TYPE-USCORP US Corporation
VEL-DROP -41% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Abiomed Europe GmbH (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

Qualcomm Incorporated · highest

85
Agios Pharmaceuticals · this assignee

45
Praxis Works · near

45
Tamron · near

45
Liebherr-verzahntech… · near

45
Tyco AMP Korea · near

45
3D Lighting… · lowest

7

What this shows Agios's Innovation Score is 45.3/100 (top 23% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Where Agios's grants concentrate

Agios Pharmaceuticals, Inc. is a focused PatentsView assignee: 16 CPC subclasses with 87.9% of grants classified under A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations). Peak complete grant year is 2018 (18 grants) versus a trough of 3 in 2023. By volume, Agios sits between Videojet Technologies Inc. and Bruker Biospin GmbH.

Agios's three-year grant acceleration

From 2019–2021 to 2022–2024, Agios Pharmaceuticals, Inc. moved from 29 to 14 grants (0.48x the prior three-year total, a multiple, not a CAGR). See the growth leaderboard.

Videojet

92
Watts Regulator

92
Willis Electric

92
Abiomed Europe

91
Anhui Huami Infor…

91
Azur Space Solar…

91
Board of Trustees…

91
Bruker Biospin

91
Agios Pharmaceuti… ◀

91

What this shows Agios holds 91 patents at rank #3,953, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Agios

By rank, the assignees closest to #3,953 in granted patent volume.

Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)

Other assignees with the most granted patents in Agios's primary technology class.

Assignees with similar portfolio profiles

Two PlainPatent-derived peer sets for Agios, neither rank-band nor same-CPC leaders (those blocks stay above).

Similar innovation score

Nearest assignees by Innovation Score (45 here).

Tamron Co., Ltd. 45 Praxis Works LLC 45 Liebherr-verzahntechnik GMBH 45 Tyco Electronics AMP Korea Co., Ltd. 45

Similar claim depth

Nearest assignees by average claims per patent (20.6 here).

Curiouser Products Inc. 20.6 avg H.B. Fuller Company 20.6 avg Nyse Holdings LLC 20.6 avg Navico Holding AS 20.6 avg

Agios's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

45 Top 23% higher than 77% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2015–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table

Agios Pharmaceuticals, Inc. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2015	7	7.7%
2016	9	9.9%
2017	12	13.2%
2018	18	19.8%
2019	10	11.0%
2020	13	14.3%
2021	6	6.6%
2022	5	5.5%
2023	3	3.3%
2024	6	6.6%
2025partial year	2	2.2%

Which technologies does Agios Pharmaceuticals, Inc. patent most?

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 80

C07D - Heterocyclic Compounds 72

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 72

C07K - Peptides 7

C07C - Acyclic OR Carbocyclic Compounds 7

C07B - General Methods OF Organic CHEMISTRY; Apparatus Therefor 6

C12Q - Measuring OR Testing Processes Involving Enzymes, Nucleic Acids OR Microorganisms ; Compositions OR Test Papers THEREFOR; Processes OF Preparing Such COMPOSITIONS; Condition-responsive Control IN Microbiological OR Enzymological Processes 6

G01N - Investigating OR Analysing Materials BY Determining Their Chemical OR Physical Properties 5

C07F - Acyclic, Carbocyclic OR Heterocyclic Compounds Containing Elements Other Than Carbon, Hydrogen, Halogen, Oxygen, Nitrogen, Sulfur, Selenium OR Tellurium 5

C12Y - Enzymes 4

Y02P - Climate Change Mitigation Technologies IN THE Production OR Processing OF Goods 4

A01N - Preservation OF Bodies OF Humans OR Animals OR Plants OR Parts Thereof ; Biocides, e.g. AS Disinfectants, AS Pesticides OR AS Herbicides ; Pest Repellants OR ATTRACTANTS; Plant Growth Regulators 2

C12N - Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media 2

A61B - DIAGNOSIS; SURGERY; Identification 1

Y02A - Technologies FOR Adaptation TO Climate Change 1

Top 15 of 16 technology areas

Where it ranks

Overall rank by patents

#3,953

of 49,997 tracked assignees

Innovation Score

45.3 out of 100

View all rankings →

Data Source

USPTO PatentsView, US granted patents 2015–2025

How is Innovation Score calculated?

What to do with this data

Agios Pharmaceuticals, Inc.'s patent record in context - here's where to go next.

Agios Pharmaceuticals, Inc.'s lead technology class is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations), 87.9% of its portfolio - see every assignee active in that class. Explore A61P
Ranked #3,953 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Agios Pharmaceuticals, Inc. against Videojet Technologies Inc., an assignee filing at a similar volume. Compare portfolios
Innovation Score of 45.3/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.